This study aimed to compare the safety and effectiveness of two different methods for fabricating and implanting Iodine-125 (\^125\^I) radioactive seed strands combined with a metal stent for treating malignant obstructive jaundice. The conventional method uses a straight seed strand placed between the stent and the bile duct wall. A novel technique was developed that uses a spiral-shaped seed strand placed inside the stent lumen. Between January 2018 and February 2024, 105 patients were randomly assigned to two groups. Group A (59 patients) received the conventional straight strand, while Group B (46 patients) received the novel spiral strand. The study compared therapeutic efficacy, the incidence of intraoperative and postoperative complications, stent patency duration, and patient survival. Both methods successfully improved liver function. However, the novel spiral technique (Group B) caused significantly fewer complications, such as bile leakage and peritonitis, compared to the conventional method (Group A). Importantly, patients in Group B also had longer stent patency (305 days vs. 277 days) and longer overall survival (345 days vs. 300 days). In conclusion, the novel spiral seed strand implantation technique is a safer and more effective treatment option for malignant obstructive jaundice.
Malignant obstructive jaundice often requires palliative drainage with self-expanding metallic stents. Combining stents with brachytherapy using Iodine-125 (\^125\^I) seed strands has been shown to prolong stent patency and patient survival compared to stenting alone. The conventional technique implants a linear seed strand between the stent and the bile duct wall, which is associated with risks of hemobilia, biliary fistula, and peritonitis due to the need for a larger puncture tract. This prospective, randomized controlled trial aimed to evaluate a novel, refined method involving a spiral-configured \^125\^I seed strand implanted within the stent lumen, hypothesizing that it would reduce procedure-related complications while maintaining or improving therapeutic efficacy. Study Design and Methods: This was a single-center, prospective, randomized controlled trial. From January 2018 to February 2024, 105 patients with inoperable malignant obstructive jaundice were enrolled and randomly allocated into two groups. Group A (Conventional, n=59): Received a straight \^125\^I seed strand implanted between the metallic stent and the bile duct wall. Group B (Novel, n=46): Received a spiral \^125\^I seed strand implanted within the lumen of the metallic stent. All patients first underwent percutaneous transhepatic biliary drainage (PTBD) for decompression, followed by the combined stent and seed strand (PTBSIS) procedure 3-7 days later. Primary and Secondary Outcomes: The primary endpoints were procedure-related complications (intraoperative and postoperative) and stent patency time. Secondary endpoints included technical success rate, improvement in liver function tests at one month, and overall patient survival. Complications assessed included nausea/vomiting, abdominal pain, hemobilia, vagal reflex, fever, biliary fistula, and biliary peritonitis. Statistical Analysis: Continuous data are presented as mean ± standard deviation or median (interquartile range). Categorical variables were compared using the Chi-square or Fisher's exact test. Stent patency and overall survival were analyzed using the Kaplan-Meier method with the log-rank test. A two-sided P-value \< 0.05 was considered statistically significant. Analyses were performed using SPSS version 22.0.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
105
This is a combined interventional radiology procedure for malignant obstructive jaundice. Under local anesthesia and fluoroscopic guidance, a self-expanding metallic biliary stent is percutaneously placed across the malignant stricture. Subsequently, a linear strand of Iodine-125 (\^125\^I) seeds, fabricated by sealing the prescribed number of seeds within a catheter, is implanted and fixed in the space between the outer wall of the stent and the bile duct wall. The \^125\^I seeds provide continuous low-dose-rate brachytherapy to inhibit tumor ingrowth and prolong stent patency.
This is a combined interventional radiology procedure for malignant obstructive jaundice. Under local anesthesia and fluoroscopic guidance, a self-expanding metallic biliary stent is percutaneously placed across the malignant stricture. Subsequently, a spiral-configured strand of Iodine-125 (\^125\^I) seeds, fabricated by shaping a linear catheter strand with boiling water (using a slightly higher seed count to compensate for foreshortening), is implanted and secured within the inner lumen of the stent. The \^125\^I seeds provide continuous low-dose-rate brachytherapy to inhibit tumor ingrowth and prolong stent patency. This method is designed to reduce tract-related injury by minimizing bile duct wall manipulation.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Stent Patency Time
The duration from the date of stent placement to the date of first documented stent re-obstruction (confirmed by imaging evidence of restenosis or occlusion). For patients who die without prior evidence of recurrent jaundice, the data will be censored at the date of death.
Time frame: From the date of randomization/stent placement until the date of documented stent re-obstruction or death from any cause, whichever occurs first, assessed up to 24 months.
Overall Survival
The time from the date of the stent placement procedure until the date of death from any cause. For patients who are alive at the end of the study, survival data will be censored at the date of the last follow-up contact.
Time frame: From the date of randomization/stent placement until the date of death from any cause, assessed up to 24 months.
Incidence of Procedure-Related Complications
The composite rate of intraoperative and postoperative adverse events. Assessed complications include nausea/vomiting, abdominal pain, hemobilia, vagus reflex, fever, biliary fistula, and biliary peritonitis. Each complication will be documented as present or absent based on clinical and diagnostic criteria.
Time frame: Intraoperative period and up to 30 days after the procedure.
Change in Serum Total Bilirubin (TBIL) Level
The absolute change in serum total bilirubin concentration (measured in μmol/L) from the pre-procedure baseline (after initial PTBD drainage) to 1 month after the combined stent and seed strand implantation procedure.
Time frame: Baseline (pre-PTBSIS, after initial PTBD) and 1 month after the PTBSIS procedure.
Change in Serum Alanine Aminotransferase (ALT) Level
The absolute change in serum alanine aminotransferase activity (measured in U/L) from the pre-procedure baseline (after initial PTBD drainage) to 1 month after the combined stent and seed strand implantation procedure.
Time frame: Baseline (pre-PTBSIS, after initial PTBD) and 1 month after the PTBSIS procedure.
Change in Serum Aspartate Aminotransferase (AST) Level
The absolute change in serum aspartate aminotransferase activity (measured in U/L) from the pre-procedure baseline (after initial PTBD drainage) to 1 month after the combined stent and seed strand implantation procedure.
Time frame: Baseline (pre-PTBSIS, after initial PTBD) and 1 month after the PTBSIS procedure.
Technical Success Rate
The proportion of procedures in which both the biliary metallic stent and the \^125\^I seeds strand are successfully and precisely deployed at the intended target lesion site, as confirmed by immediate post-procedure fluoroscopy demonstrating unobstructed flow of contrast medium through the stent lumen into the duodenum.
Time frame: Assessed immediately upon completion of the stent and seed strand implantation procedure.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.